Publications

Mesenchymal Stem Cells and Fibroblasts Contribute to Microvascular Proliferation in Glioblastoma and are Correlated with Immunosuppression and Poor Outcome
- PMID = 40131028
- DOI = 10.1158/2326-6066.CIR-24-0743
- Citation = Poon CC, Herbrich SM, Chen Y, Hossain A, Fuller GN, Jindal S, Basu S, Ledbetter D, Macaluso M, Phillips LM, Gumin J, He Z, Parker Kerrigan BC, Singh SK, Singh P, Zaman MF, Ng Tang D, Goswami S, Lang FF, Sharma P. Mesenchymal Stem Cells and Fibroblasts Contribute to Microvascular Proliferation in Glioblastoma and are Correlated with Immunosuppression and Poor Outcome. Cancer Immunol Res. 2025 Jun 4;13(6):804-820. doi: 10.1158/2326-6066.CIR-24-0743. PMID: 40131028; PMCID: PMC12175251.

Investigative needle core biopsies support multimodal deep-data generation in glioblastoma
- PMID = 40295505
- DOI = 10.1038/s41467-025-58452-8
- Citation = Yu KKH, Basu S, Baquer G, Ahn R, Gantchev J, Jindal S, Regan MS, Abou-Mrad Z, Prabhu MC, Williams MJ, D'Souza AD, Malinowski SW, Hopland K, Elhanati Y, Stopka SA, Stortchevoi A, Couturier C, He Z, Sun J, Chen Y, Espejo AB, Chow KH, Yerrum S, Kao PL, Kerrigan BP, Norberg L, Nielsen D; GBM TeamLab; Puduvalli VK, Huse J, Beroukhim R, Kim BYS, Goswami S, Boire A, Frisken S, Cima MJ, Holdhoff M, Lucas CG, Bettegowda C, Levine SS, Bale TA, Brennan C, Reardon DA, Lang FF, Chiocca EA, Ligon KL, White FM, Sharma P, Tabar V, Agar NYR. Investigative needle core biopsies support multimodal deep-data generation in glioblastoma. Nat Commun. 2025 Apr 28;16(1):3957. doi: 10.1038/s41467-025-58452-8. PMID: 40295505; PMCID: PMC12037860.

Neoadjuvant immune checkpoint therapy: Enabling insights into fundamental human immunology and clinical benefit
- PMID = 40118048
- DOI = 10.1016/j.ccell.2025.03.005
- Citation = Pauken KE, Alhalabi O, Goswami S, Sharma P. Neoadjuvant immune checkpoint therapy: Enabling insights into fundamental human immunology and clinical benefit. Cancer Cell. 2025 Apr 14;43(4):623-640. doi: 10.1016/j.ccell.2025.03.005. Epub 2025 Mar 20. PMID: 40118048.

Immune checkpoint inhibitors plus debulking surgery for patients with metastatic renal cell carcinoma: clinical outcomes and immunological correlates of a prospective pilot trial
- PMID = 39984485
- DOI = 10.1038/s41467-025-57009-z
- Citation = Goswami S, Gao J, Basu S, Shapiro DD, Karam JA, Tidwell RS, Ahrar K, Campbell MT, Shen Y, Trevino AE, Mayer AT, Espejo AB, Seua C, Macaluso MD, Chen Y, Liu W, He Z, Yadav SS, Wang Y, Rao P, Zhao L, Zhang J, Jindal S, Tannir NM, Futreal A, Wang L, Sharma P. Immune checkpoint inhibitors plus debulking surgery for patients with metastatic renal cell carcinoma: clinical outcomes and immunological correlates of a prospective pilot trial. Nat Commun. 2025 Feb 21;16(1):1846. doi: 10.1038/s41467-025-57009-z. PMID: 39984485; PMCID: PMC11845590.

Next-generation combination approaches for immune checkpoint therapy
- PMID = 39587347
- DOI = 10.1038/s41590-024-02015-4
- Citation = Goswami S, Pauken KE, Wang L, Sharma P. Next-generation combination approaches for immune checkpoint therapy. Nat Immunol. 2024 Dec;25(12):2186-2199. doi: 10.1038/s41590-024-02015-4. Epub 2024 Nov 25. PMID: 39587347.

Histone lactylation drives CD8⁺ T cell metabolism and function
- PMID = 38854142
- DOI = 10.1038/s41590-024-01985-9
- Citation = Raychaudhuri D, Singh P, Chakraborty B, Hennessey M, Tannir AJ, Byregowda S, Natarajan SM, Trujillo-Ocampo A, Im JS, Goswami S. Histone lactylation drives CD8+ T cell metabolism and function. Nat Immunol. 2024 Oct 7. doi: 10.1038/s41590-024-01985-9. Epub ahead of print. PMID: 39375549.

Loss of ARID1A 'loops' in STING
- PMID = 39060141
- DOI = 10.1016/j.it.2024.07.001
- Citation = Goswami S, Sharma P. Loss of ARID1A 'loops' in STING. Trends Immunol. 2024 Aug;45(8):568-570. doi: 10.1016/j.it.2024.07.001. Epub 2024 Jul 25. PMID: 39060141.

TSG-6+ cancer-associated fibroblasts modulate myeloid cell responses and impair anti-tumor response to immune checkpoint therapy in pancreatic cancer
- PMID = 38987547
- DOI = 10.1038/s41467-024-49189-x
- Citation = Anandhan S, Herbrich S, Goswami S, Guan B, Chen Y, Macaluso MD, Jindal S, Natarajan SM, Andrewes SW, Xiong L, Nagarajan A, Basu S, Tang DN, Liu J, Min J, Maitra A, Sharma P. TSG-6+ cancer-associated fibroblasts modulate myeloid cell responses and impair anti-tumor response to immune checkpoint therapy in pancreatic cancer. Nat Commun. 2024 Jul 10;15(1):5291. doi: 10.1038/s41467-024-49189-x. PMID: 38987547; PMCID: PMC11237123.

KDM6B-mediated reprogramming of myeloid cells regulates the response to immunotherapy
- PMID = 37700093
- DOI = 10.1038/s43018-023-00621-z
- Citation= Goswami S. KDM6B-mediated reprogramming of myeloid cells regulates the response to immunotherapy. Nat Cancer. 2023 Oct;4(10): 1408-1409. doi: 10.1038/s43018-023-00621-z. PMID: 37700093.

Myeloid-specific KDM6B inhibition sensitizes glioblastoma to PD1 blockade
- PMID = 37653141
- DOI = 10.1038/s43018-023-00620-0
- Citation = Goswami S, Raychaudhuri D, Singh P, Natarajan SM, Chen Y, Poon C, Hennessey M, Tannir AJ, Zhang J, Anandhan S, Kerrigan BP, Macaluso MD, He Z, Jindal S, Lang FF, Basu S, Sharma P. Myeloid-specific KDM6B inhibition sensitizes glioblastoma to PD1 blockade. Nat Cancer. 2023 Oct;4(10):1455-1473. doi: 10.1038/s43018-023-00620-0. Epub 2023 Aug 31. PMID: 37653141.

Immune checkpoint therapy—current perspectives and future directions
- PMID = 37059068
- DOI = 10.1016/j.cell.2023.03.006
- Citation = Sharma P, Goswami S, Raychaudhuri D, Siddiqui BA, Singh P, Nagarajan A, Liu J, Subudhi SK, Poon C, Gant KL, Herbrich SM, Anandhan S, Islam S, Amit M, Anandappa G, Allison JP. Immune checkpoint therapy-current perspectives and future directions. Cell. 2023 Apr 13;186(8):1652-1669. doi: 10.1016/j.cell.2023.03.006. PMID: 37059068.

Myeloid cell-targeted therapies for solid tumours
- PMID = 35697799
- DOI = 10.1038/s41577-022-00737-w
- Citation = Goswami S, Anandhan S, Raychaudhuri D, Sharma P. Myeloid cell-targeted therapies for solid tumours. Nat Rev Immunol. 2023 Feb;23(2):106-120. doi: 10.1038/s41577-022-00737-w. Epub 2022 Jun 13. PMID: 35697799.

Myeloid cell-targeted therapies for solid tumours
- PMID = 35697799
- DOI  = 10.1038/s41577-022-00737-w
- Citation = Goswami S, Anandhan S, Raychaudhuri D, Sharma P. Myeloid cell-targeted therapies for solid tumours. Nat Rev Immunol. 2022 Jun 13. doi: 10.1038/s41577-022-00737-w. Epub ahead of print. PMID: 35697799.

A composite T-cell biomarker in pre-treatment blood samples correlates with detection of immune-related adverse events
- PMID = 35290784
- DOI = 10.1016/j.ccell.2022.02.015
- Citation = Goswami S, Siddiqui BA, Subudhi SK, Basu S, Yadav SS, Diab A, Sharma P. A composite T cell biomarker in pre-treatment blood samples correlates with detection of immune-related adverse events. Cancer Cell. 2022 Mar 14;40(3):249-251. doi: 10.1016/j.ccell.2022.02.015. PMID: 35290784.

A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following profession on antiangiogenic therapy
- PMID = 35442707
- DOI = 10.1126/scitranslmed.abm6420
- Citation = Msaouel P, Goswami S, Thall PF, Wang X, Yuan Y, Jonasch E, Gao J, Campbell MT, Shah AY, Corn PG, Tam AL, Ahrar K, Rao P, Sircar K, Cohen L, Basu S, Duan F, Jindal S, Zhang Y, Chen H, Yadav SS, Shazer R, Der-Torossian H, Allison JP, Sharma P, Tannir NM. A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy. Sci Transl Med. 2022 Apr 20;14(641):eabm6420. doi: 10.1126/scitranslmed.abm6420. Epub 2022 Apr 20. PMID: 35442707.

Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events
- PMID = 34326169
- DOI = 10.1136/jitc-2021-002850
- Citation = Siddiqui BA, Gheeya JS, Goswamy R, Bathala TK, Surasi DS, Gao J, Shah A, Campbell MT, Msaouel P, Goswami S, Wang J, Zurita AJ, Jonasch E, Corn PG, Aparicio AM, Siefker-Radtke AO, Sharma P, Subudhi SK, Tannir N. Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events. J Immunother Cancer. 2021 Jul;9(7):e002850. doi: 10.1136/jitc-2021-002850. PMID: 34326169; PMCID: PMC8323401.

Frontiers in cancer immunotherapy—a symposium report
- PMID = 33184911
- DOI = 10.1111/nyas.14526
- Citation = Cable J, Greenbaum B, Pe'er D, Bollard CM, Bruni S, Griffin ME, Allison JP, Wu CJ, Subudhi SK, Mardis ER, Brentjens R, Sosman JA, Cemerski S, Zavitsanou AM, Proia T, Egeblad M, Nolan G, Goswami S, Spranger S, Mackall CL. Frontiers in cancer immunotherapy—a symposium report. Ann N Y Acad Sci. 2021 Apr;1489(1):30-47. doi: 10.1111/nyas.14526. Epub 2020 Nov 13. PMID: 33184911.

Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors
- PMID = 33187886
- DOI = 10.1016/j.urolonc.2020.10.019
- Citation = Chahoud J, Msaouel P, Ross JA, McCormick BZ, Bathala TK, Gao J, Horn R, Xiao L, Sircar K, Campbell MT, Shah AY, Goswami S, Zurita AJ, Jonasch E, Matin SF, Wood CG, Karam JA, Sharma P, Tannir NM. Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors. Urol Oncol. 2021 Feb;39(2):134.e9-134.e16. doi: 10.1016/j.urolonc.2020.10.019. Epub 2020 Nov 10. PMID: 33187886.

The next decade of immune checkpoint therapy
- PMID = 33811120
- DOI = 10.1158/2159-8290.CD-20-1680
- Citation = Sharma P, Siddiqui BA, Anandhan S, Yadav SS, Subudhi SK, Gao J, Goswami S, Allison JP. The Next Decade of Immune Checkpoint Therapy. Cancer Discov. 2021 Apr;11(4):838-857. doi: 10.1158/2159-8290.CD-20-1680. PMID: 33811120.

ARID1A mutation plus CSCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC
- PMID = 32554706
- DOI = 10.1126/scitranslmed.abc4220
- Citation = Goswami S, Chen Y, Anandhan S, Szabo PM, Basu S, Blando JM, Liu W, Zhang J, Natarajan SM, Xiong L, Guan B, Yadav SS, Saci A, Allison JP, Galsky MD, Sharma P. ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC. Sci Transl Med. 2020 Jun 17;12(548):eabc4220. doi: 10.1126/scitranslmed.abc4220. PMID: 32554706.

Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma
- PMID = 31873309
- DOI = 10.1038/s41591-019-0694-x
- Citation = Goswami S, Walle T, Cornish AE, Basu S, Anandhan S, Fernandez I, Vence L, Blando J, Zhao H, Yadav SS, Ott M, Kong LY, Heimberger AB, de Groot J, Sepesi B, Overman M, Kopetz S, Allison JP, Pe'er D, Sharma P. Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma. Nat Med. 2020 Jan;26(1):39-46. doi: 10.1038/s41591-019-0694-x. Epub 2019 Dec 23. PMID: 31873309; PMCID: PMC7182038.

Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma
- PMID = 33046869
- DOI = 10.1038/s41591-020-1086-y
- Citation = Gao J, Navai N, Alhalabi O, Siefker-Radtke A, Campbell MT, Tidwell RS, Guo CC, Kamat AM, Matin SF, Araujo JC, Shah AY, Msaouel P, Corn P, Wang J, Papadopoulos JN, Yadav SS, Blando JM, Duan F, Basu S, Liu W, Shen Y, Zhang Y, Macaluso MD, Wang Y, Chen J, Zhang J, Futreal A, Dinney C, Allison JP, Goswami S, Sharma P. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med. 2020 Dec;26(12):1845-1851. doi: 10.1038/s41591-020-1086-y. Epub 2020 Oct 12. PMID: 33046869.

Targeting cd73 may improve immunotherapy efficacy in glioblastoma
- PMID = N/A (not on PubMed)
- Citation = Goswami, S., Walle, T., Cornish, A. E., Basu, S., Anandhan, S., Fernandez, I., & Vence, L. M. (2020). Targeting cd73 may improve immunotherapy efficacy in glioblastoma. Cancer discovery, 10(2), 175. https://doi.org/10.1158/2159-8290.CD-RW2020-005

Blockade of CTLA-4 and PD-1 enhances adoptive T-cell therapy efficacy in an ICOS-mediated manner
- PMID = 31466995
- DOI = 10.1158/2326-6066.CIR-18-0873
- Citation = Shi LZ, Goswami S, Fu T, Guan B, Chen J, Xiong L, Zhang J, Ng Tang D, Zhang X, Vence L, Blando J, Allison JP, Collazo R, Gao J, Sharma P. Blockade of CTLA-4 and PD-1 Enhances Adoptive T-cell Therapy Efficacy in an ICOS-Mediated Manner. Cancer Immunol Res. 2019 Nov;7(11):1803-1812. doi: 10.1158/2326-6066.CIR-18-0873. Epub 2019 Aug 29. PMID: 31466995.

A potential biomarker for anti-PD-1 immunotherapy
- PMID = 29414936
- DOI = 10.1038/nm.4489
- Citation = Goswami S, Basu S, Sharma P. A potential biomarker for anti-PD-1 immunotherapy. Nat Med. 2018 Feb 7;24(2):123-124. doi: 10.1038/nm.4489. PMID: 29414936.

Modulation of EZH2 expression in T-cells improves efficacy of anti-CTLA-4 therapy
- PMID = 29905573
- DOI = 10.1172/JCI99760
- Citation = Goswami S, Apostolou I, Zhang J, Skepner J, Anandhan S, Zhang X, Xiong L, Trojer P, Aparicio A, Subudhi SK, Allison JP, Zhao H, Sharma P. Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy. J Clin Invest. 2018 Aug 31;128(9):3813-3818. doi: 10.1172/JCI99760. Epub 2018 Jul 30. PMID: 29905573; PMCID: PMC6118570.

Genetic biomarker for cancer immunotherapy
- PMID = 28751597
- DOI = 10.1126/science.aao1894
- Citation = Goswami S, Sharma P. Genetic biomarker for cancer immunotherapy. Science. 2017 Jul 28;357(6349):358. doi: 10.1126/science.aao1894. PMID: 28751597.